Shares of BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) fell 5.9% on Friday . The company traded as low as $1.02 and last traded at $1.04. 85,599 shares traded hands during mid-day trading, an increase of 4,505% from the average session volume of 1,859 shares. The stock had previously closed at $1.11.
BriaCell Therapeutics Stock Performance
The stock has a 50 day moving average of $1.68 and a two-hundred day moving average of $2.97. The firm has a market capitalization of $802,880.00, a P/E ratio of -0.27 and a beta of 1.09.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- The 3 Best Blue-Chip Stocks to Buy Now
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Top Biotech Stocks: Exploring Innovation Opportunities
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
